Literature DB >> 18534346

Guiding patients through the choices for treating vestibular schwannomas: balancing options and ensuring informed consent. 2007.

Douglas D Backous1, Huong T Pham.   

Abstract

Counseling patients who are diagnosed with vestibular schwannomas, formerly known as acoustic neuromas, can be challenging. The health care provider has the responsibility to explain, in understandable language, to the patient or legal representative the proposed treatment options, risks and complications associated with each form of treatment, and alternatives to treatment, including no therapy. Patients should be encouraged to gather information before making a treatment decision. For the physicians managing these patients, information should be delivered in a balanced way to ensure patient understanding of their options leading to adequate informed consent.

Entities:  

Mesh:

Year:  2008        PMID: 18534346     DOI: 10.1016/j.nec.2008.02.004

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  3 in total

1.  An audiological analysis of stereotactic radiation strategies to preserve hearing in patients with vestibular schwannomas.

Authors:  Shoshana Movsas; Michael Hefferly; Benjamin Movsas; Valeriy Shafiro
Journal:  J Radiosurg SBRT       Date:  2014

2.  Does where you live influence how your vestibular schwannoma is managed? Examining geographical differences in vestibular schwannoma treatment across the United States.

Authors:  Matthew L Carlson; Amy E Glasgow; Brandon R Grossardt; Elizabeth B Habermann; Michael J Link
Journal:  J Neurooncol       Date:  2016-06-22       Impact factor: 4.130

3.  Long-Term Hearing Outcomes Following Stereotactic Radiosurgery in Vestibular Schwannoma Patients-A Retrospective Cohort Study.

Authors:  Peter L Santa Maria; Yangyang Shi; Richard K Gurgel; C Eduardo Corrales; Scott G Soltys; Chloe Santa Maria; Kevin Murray; Steven D Chang; Nikolas H Blevins; Iris C Gibbs; Robert K Jackler
Journal:  Neurosurgery       Date:  2019-10-01       Impact factor: 4.654

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.